October 5-6, 2026
Madrid, Spain
Driving Innovation in Parkinsons Disease Research and Care.
It is our pleasure to welcome you to the 12th International Conference on Parkinsons, taking place on October 5–6, 2026, in Madrid, Spain.
Theme: Hope in Motion: Empowering Lives with Parkinsons
Parkinsons 2026 provides a unique forum for exchanging ideas, presenting pioneering research, and exploring the latest advancements in Parkinsons, Neurology, and Brain health. The conference will showcase groundbreaking studies in Genetics, innovative approaches in Surgery, and emerging discoveries related to Alzheimers, Dementia, and other neurodegenerative disorders. Through insightful scientific sessions, expert-led discussions, and collaborative networking opportunities, participants will engage with specialists who are driving progress in neuroscience and transforming the future of neurological care.
As we face the growing challenges of Parkinsons disease worldwide, collaboration and innovation remain essential. This meeting aims to encourage meaningful partnerships, inspire new research directions, and promote solutions that can enhance patient care and quality of life.
We are delighted to have you join us for this exciting event and look forward to two days of learning, networking, and scientific discovery. Together, we can help drive progress and create a brighter future for individuals affected by Parkinsons disease.
Sincerely,
Serena Williams
Program Manager | Parkinsons 2026
E-Mail ID: parkinsons@alliedgathering.com
Parkinsons 2026 designed to encourage knowledge sharing and international collaboration, and will create meaningful opportunities for professional interaction, research partnerships, and interdisciplinary discussions. By bringing together experts from various specialties, the conference aims to inspire new discoveries, strengthen scientific networks, and contribute to the advancement of neurological health on a global scale.
Building Connections for Greater Impact
More than a scientific meeting, Parkinsons 2026 is a hub for collaboration and knowledge exchange. The conference brings together researchers, clinicians, academicians, and industry professionals to share expertise, establish partnerships, and spark new ideas across diverse areas of neuroscience. Through meaningful interactions and interdisciplinary discussions, attendees will contribute to advancing research, innovation, and patient care worldwide.
Benefits of Participation:
Join us in Madrid and be part of Parkinsons 2026 to advance Parkinsons research, strengthen scientific collaboration, and improve patient outcomes worldwide.
Session 1: Neurobiology
Description:
In Parkinsons 2026, this session explores the neurobiology of Parkinsons disease, focusing on Brain function, neuronal loss, dopamine imbalance, and the role of Genetics in disease progression. It also highlights connections with Neurology, Alzheimers, Stroke, and Dementia, while presenting advances in Surgery, therapeutic strategies, and Epidemiology research to improve understanding and treatment of Parkinsons disease.
Tracks:
Track 1.1: Neuronal Function
Track 1.2: Dopaminergic Systems
Track 1.3: Synaptic Signaling
Track 1.4: Neural Circuits
Track 1.5: Brain Plasticity
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 2: Pathophysiology
Description:
In Parkinsons 2026, this session focuses on the underlying pathophysiological mechanisms of Parkinsons disease, examining how cellular and molecular changes in the Brain lead to progressive neurodegeneration. It highlights key processes such as dopaminergic neuron loss, protein misfolding, oxidative stress, and neuroinflammation. The session also explores how these mechanisms affect Neurology, contribute to Stroke risk and cognitive decline associated with Dementia, offering insights into disease progression and potential therapeutic targets.
Tracks:
Track 2.1: Dopaminergic Degeneration
Track 2.2: Alpha-Synuclein
Track 2.3: Protein Misfolding
Track 2.4: OxidativeStress
Track 2.5: Neuroinflammation
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 3: Biomarkers
Description:
In Parkinsons 2026, this session focuses on the discovery and application of biomarkers for Parkinsons disease, emphasizing their role in early detection, accurate diagnosis, and monitoring disease progression. It explores advances in molecular, Genetics, imaging, and digital biomarkers, along with their potential to improve clinical decision-making and support the development of targeted therapies, including Surgery-based approaches. The session also examines biomarker applications in related disorders such as Alzheimers disease and highlights findings from Epidemiology studies that are shaping personalized medicine and enabling more effective management of Parkinsons disease.
Tracks:
Track 3.1: Diagnostic Markers
Track 3.2: Molecular Biomarkers
Track 3.3: Imaging Biomarkers
Track 3.4: Fluid Biomarkers
Track 3.5: Genetic Markers
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 4: Genetics
Description:
In Parkinsons 2026, this session explores the genetic foundations of Parkinsons disease, focusing on how inherited and sporadic genetic variations contribute to disease onset and progression. It highlights key gene mutations, genetic risk factors, and advances in genomic research that are improving our understanding of Parkinsons, Brain function, Neurology, Stroke, and Dementia-related mechanisms. The session also examines the role of genetics in early detection, personalized medicine, and the development of targeted therapies, providing valuable insights into the interconnected fields of Parkinsons, Brain health, Neurology, Stroke, and Dementia research.
Tracks:
Track 4.1: Gene Mutations
Track 4.2: Genetic Risk
Track 4.3: Familial Parkinsons
Track 4.4: Sporadic Cases
Track 4.5: Genomics
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 5: Neurodegeneration
Description:
In Parkinsons 2026, this session focuses on the progressive loss of neurons that defines Parkinsons disease, with an emphasis on the degeneration of dopaminergic cells in the brain. It explores the cellular and molecular processes driving neuronal damage, including protein aggregation, mitochondrial dysfunction, and impaired cellular repair mechanisms. The session highlights emerging connections between Parkinsons, Genetics, Alzheimer, Surgery, and Epidemiology, providing a broader understanding of disease mechanisms and clinical outcomes.
Tracks:
Track 5.1: Neuronal Loss
Track 5.2: Dopaminergic Neurons
Track 5.3: Alpha Synuclein
Track 5.4: Protein Aggregation
Track 5.5: Mitochondrial Damage
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 6: Dopamine
Description:
In Parkinsons 2026, this session centers on the critical role of dopamine in Parkinsons disease, exploring how its depletion disrupts motor control and contributes to a wide range of symptoms. It examines the functioning of dopaminergic pathways, the impact of neuronal loss on dopamine production, and the resulting imbalance in brain signaling. The session highlights the importance of Brain function, Neurology, and Stroke research in understanding neurotransmitter regulation and disease progression.
Tracks:
Track 6.1: Dopamine Pathways
Track 6.2: Dopaminergic Neurons
Track 6.3: Neurotransmission
Track 6.4: Dopamine Deficiency
Track 6.5: Basal Ganglia
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 7: Cognition
Description:
In Parkinsons 2026, this session focuses on cognitive changes associated with Parkinsons disease, including impairments in memory, attention, executive function, and decision-making. It explores the neurological basis of cognitive decline, its progression over time, and its impact on daily functioning and quality of life. The session highlights the close relationship between Parkinsons, Genetics, and Alzheimer research in understanding the mechanisms underlying cognitive impairment and neurodegeneration.
Tracks:
Track 7.1: Cognitive Decline
Track 7.2: Memory
Track 7.3: Executive Function
Track 7.4: Attention
Track 7.5: Decision Making
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 8: Psychiatry
Description:
In Parkinsons 2026, this session addresses the psychiatric and behavioural aspects of Parkinsons disease, focusing on conditions such as depression, anxiety, psychosis, and mood disorders that commonly accompany the disease. It explores the neurobiological links between Parkinsons and mental health, highlighting the role of the Brain and advances in Neurology that help explain the development of these complex symptoms. The session also examines how cognitive and emotional changes may overlap with conditions such as Dementia, affecting patient well-being and quality of life. In addition, it discusses the influence of cerebrovascular factors, including Stroke, on neurological and psychiatric outcomes. The session highlights advances in diagnosis, management strategies, and integrated care approaches for improving mental health outcomes in Parkinsons patients.
Tracks:
Track 8.1: Depression
Track 8.2: Anxiety
Track 8.3: Psychosis
Track 8.4: Mood Disorders
Track 8.5: Behavioural Changes
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 9: Pharmacology
Description:
In Parkinsons 2026, this session explores the pharmacological management of Parkinsons disease, focusing on current and emerging drug therapies for motor and non-motor symptoms. It highlights the role of Genetics in personalized treatment, insights from Alzheimer research, and the contribution of Epidemiology to understanding treatment outcomes. The session also discusses how Surgery and medication-based approaches work together to improve patient care and slow disease progression.
Tracks:
Track 9.1: Drug Therapy
Track 9.1: Levodopa
Track 9.1: Dopamine Agonists
Track 9.1: MAO Inhibitors
Track 9.1: COMT Inhibitors
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 10: Therapeutics
Description:
In Parkinsons 2026, this session focuses on current and emerging therapeutic strategies for Parkinsons disease, aiming to improve symptom management and slow disease progression. It highlights advances in Brain research that are driving the development of innovative treatment approaches and explores the role of Neurology in optimizing patient care. The session covers a broad spectrum of therapies, including pharmacological interventions, advanced treatments, and novel modalities. It also examines the impact of conditions such as Stroke and Dementia on treatment planning, while showcasing innovations in personalized therapies, combination treatments, and disease-modifying strategies designed to enhance patient outcomes and quality of life.
Tracks:
Track 10.1: Drug Therapies
Track 10.2: Advanced Therapies
Track 10.3: Combination Therapy
Track 10.4: Disease Modification
Track 10.5: Neuro protection
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 11: Neurosurgery
Description:
In Parkinsons 2026, this session focuses on surgical interventions for Parkinsons disease, highlighting advances in Surgery such as deep brain stimulation and emerging neurosurgical techniques. It also explores insights from Alzheimer research and findings from Epidemiology studies to improve patient selection, treatment outcomes, and long-term therapeutic benefits.
Tracks:
Track 11.1: Deep Brain Stimulation
Track 11.2: Functional Neurosurgery
Track 11.3: Surgical Targets
Track 11.4: Basal Ganglia
Track 11.5: Neuro stimulation
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 12: Rehabilitation
Description:
In Parkinsons 2026, this session focuses on rehabilitation strategies designed to improve mobility, function, and quality of life for individuals with Parkinsons disease. It highlights the role of Neurology in developing effective rehabilitation approaches and examines how therapies can address challenges associated with Stroke and related neurological impairments. The session also explores multidisciplinary care, including physical, occupational, and speech therapy, while considering the impact of Dementia on patient function and independence. Innovative rehabilitation techniques, personalized care plans, and technology-assisted interventions are also discussed to support long-term well-being and quality of life.
Tracks:
Track 12.1: Physical Therapy
Track 12.2: Occupational Therapy
Track 12.3: Speech Therapy
Track 12.4: Motor Rehabilitation
Track 12.5: Balance Training
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 13: Nutrition
Description:
In Parkinsons 2026, this session explores the role of nutrition in the management of Parkinsons disease, focusing on how dietary choices can influence symptom control, medication effectiveness, and overall well-being. It highlights how Genetics may affect nutritional needs and treatment responses, while insights from Alzheimer research contribute to a better understanding of diet and brain health. The session also addresses challenges such as weight changes and swallowing difficulties, and discusses dietary strategies that support quality of life. In addition, findings from Epidemiology help identify nutritional trends and outcomes in Parkinsons populations, while considerations related to Surgery and recovery further emphasize the importance of personalized nutritional care.
Tracks:
Track 13.1: Dietary Management
Track 13.2: Nutritional Support
Track 13.3: Brain Nutrition
Track 13.4: Antioxidants
Track 13.5: Gut Health
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 14: Exercise
Description:
In Parkinsons 2026, this session highlights the vital role of physical activity in managing Parkinsons disease, focusing on how structured exercise can improve mobility, balance, strength, and overall quality of life. It explores the contributions of Neurology to understanding the benefits of exercise on brain function and symptom management. The session also examines how physical activity can support recovery and functional improvement in individuals affected by Stroke, while addressing cognitive and behavioral challenges associated with Dementia. Evidence-based exercise programs, personalized activity plans, and innovative approaches to promote long-term adherence and patient well-being are also discussed.
Tracks:
Track 14.1: Physical Activity
Track 14.2: Mobility Training
Track 14.3: Balance
Track 14.4: Strength Training
Track 14.5: Flexibility
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 15: Digital Health
Description:
In Parkinsons 2026, this session explores the role of digital health technologies in Parkinsons disease management, highlighting mobile applications, wearable devices, and remote monitoring systems. It examines the integration of Genetics data for personalized care, insights from Alzheimer research, digital support for Surgery outcomes, and Epidemiology-driven data analysis to improve diagnosis, symptom tracking, and patient care.
Tracks:
Track 15.1: Mobile Health
Track 15.2: Wearables
Track 15.3: Remote Monitoring
Track 15.4: Tele health
Track 15.5: Health Apps
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 16: Artificial Intelligence
Description:
In Parkinsons 2026, this session explores the transformative role of artificial intelligence in Parkinsons disease research, diagnosis, and care. It highlights how AI-driven tools are being used to analyze complex datasets, improve early detection, and enhance understanding of Brain function and disease mechanisms. The session also examines the contributions of Neurology to AI-based clinical decision-making and personalized treatment strategies. In addition, AI applications in predicting outcomes related to Stroke and identifying cognitive changes associated with Dementia are discussed, showcasing how advanced analytics can improve patient care and outcomes.
Tracks:
Track 16.1: Machine Learning
Track 16.2: Deep Learning
Track 16.3: Predictive Modeling
Track 16.4: Data Analytics
Track 16.5: AIin Diagnosis
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 17: Telemedicine
Description:
In Parkinsons 2026, this session focuses on the role of telemedicine in improving access to care for individuals with Parkinsons disease. It explores how virtual consultations, remote monitoring, and digital platforms enable continuous patient management, particularly in remote and underserved regions. The session examines how Genetics can support personalized telehealth approaches and highlights insights from Alzheimer research that enhance remote cognitive assessment. It also discusses the use of telemedicine in pre- and post-Surgery care, improving patient follow-up and recovery monitoring. In addition, findings from Epidemiology help guide telehealth strategies and population-based care models, supporting timely, effective, and patient-centered Parkinsons disease management.
Tracks:
Track 17.1: Tele consultation
Track 17.2: Remote Care
Track 17.3: Virtual Visits
Track 17.4: Remote Monitoring
Track 17.5: Digital Platforms
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 18: PatientCare
Description:
In Parkinsons 2026, this session focuses on comprehensive, patient-centered care approaches in Parkinsons disease, emphasizing the importance of individualized treatment plans and holistic management. It explores how advances in Brain research are improving the understanding of patient needs and guiding personalized care strategies. The session also highlights the role of Neurology in addressing both motor and non-motor symptoms to enhance daily functioning and quality of life. Consideration is given to challenges associated with Stroke and the cognitive impacts of Dementia, ensuring a well-rounded approach to patient support. The session further emphasizes the value of multidisciplinary teams, caregiver involvement, and supportive services in delivering effective and compassionate care.
Tracks:
Track 18.1: Patient Centered Care
Track 18.2: Symptom Management
Track 18.3: Quality Of Life
Track 18.4: Multidisciplinary Care
Track 18.5: Care Coordination
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Session 19: Clinical Trials
Description:
In Parkinsons 2026, this session focuses on clinical trials in Parkinsons disease, highlighting studies of new drugs, therapies, and Surgery-based interventions. It explores the role of Genetics in personalized medicine, insights from Alzheimer research, and the contribution of Epidemiology to trial design, recruitment, and treatment evaluation.
Tracks:
Track 19.1: Trial Design
Track 19.2: Drug Trials
Track 19.3: Therapeutic Studies
Track 19.4: Patient Recruitment
Track 19.5: Clinical Endpoints
Related Conferences:
Parkinsons 2026 | Parkinson Conferences | Brain and Neurology Congresses | Stroke and Dementia Summits | Genetics and Alzheimers Disease Conferences | Epidemiology and Public Health Forums | Brain Disorders and Neurodegenerative Diseases Meetings | Parkinsons Surgery and Therapeutics Conferences | Clinical Neurology and Brain Research Congresses | Dementia, Alzheimers and Parkinsons Disease Symposia
Related Associations:
International Parkinson and Movement Disorder Society | World Federation of Neurology | Parkinsons Foundation | International Brain Research Organization | European Academy of Neurology | World Stroke Organization | Alzheimers Association | International Epidemiological Association
Session 20: Innovations
Description:
In Parkinsons 2026, this session highlights the latest innovations in Parkinsons disease research and care, showcasing advances in Brain science and Neurology that improve diagnosis and treatment. It also explores emerging solutions related to Stroke and Dementia, emphasizing how interdisciplinary innovation is advancing patient care and therapeutic development.
Tracks:
Track 20.1: Emerging Technologies
Track 20.2: Novel Therapies
Track 20.3: Biomedical Innovation
Track 20.4: Neuro technology
Track 20.5: Digital Solutions
Related Journals:
Journal of Parkinsons Disease | Parkinsonism & Related Disorders | Brain | Neurology | Stroke | Alzheimers & Dementia | Neurogenetics | Journal of Neurology, Neurosurgery & Psychiatry
Related Societies:
International Parkinson and Movement Disorder Society | Parkinsons Foundation | Society for Neuroscience | International Brain Research Organization | World Federation of Neurology | European Academy of Neurology | World Stroke Organization | Alzheimers Association
Market Analysis of Parkinsons Conference (Past Decade: 2016–2026)
Over the past decade, the landscape of Parkinsons disease research and related scientific conferences has experienced steady and significant growth, driven by rising disease prevalence, expanding research investments, and increasing global awareness.
1. Rising Global Disease Burden Driving Demand
Parkinsons disease affects over 10 million people worldwide, with cases increasing due to aging populations.
The global burden is expected to grow dramatically, with projections suggesting a more than doubling of cases by 2050.
This surge has created a strong demand for knowledge exchange platforms, increasing the number and scale of international conferences.
2. Expansion of the Parkinsons Treatment Market
The Parkinsons treatment market has grown steadily, reaching ~USD 5.65 billion in 2024 and projected to exceed USD 7.5 billion by 2030.
Broader industry projections indicate continued expansion, with the overall Parkinsons market expected to grow significantly in the coming decade.
This economic growth has fueled higher investments in R&D, increasing conference participation from pharmaceutical, biotech, and healthcare sectors.
3. Growth in Clinical Trials & Research Activities
The Parkinsons clinical trials market reached over USD 1.1 billion in 2024 and is projected to grow at a 7%+ CAGR.
Neurology-specific trials are also expanding steadily, reinforcing continuous innovation in treatment strategies.
This surge in research activity has directly increased the need for scientific forums, boosting conference frequency and attendance.
Graph:
4. Regional Growth Trends
North America and Europe have traditionally dominated Parkinsons research and conferences.
However, Asia-Pacific is emerging as the fastest-growing region, driven by population aging and increasing healthcare investment.
This shift has led to more international collaborations and rotating global conference locations.
5. Future Outlook (2026 and Beyond)
Continued growth in patient population and healthcare costs (e.g., $82+ billion annually in the U.S. alone) will sustain research demand.
Conferences are expected to become more:
Interdisciplinary (AI, genetics, neurology integration)
Technology-driven (virtual platforms, real-time data sharing)
Industry-collaborative (academia + pharma partnerships)